Publicacións en colaboración con investigadores/as de Hospital Universitario Virgen de la Victoria (39)

2024

  1. Clinical and Epidemiological Characteristics of Patients Being Treated for Scabies in Spain: Opportunities for Improvement — A Multicenter Cross-Sectional CLINI-AEDV Study

    Actas Dermo-Sifiliograficas, Vol. 115, Núm. 1, pp. 36-47

  2. Safety of biologic therapy in combination with methotrexate in moderate to severe psoriasis: a cohort study from the BIOBADADERM registry

    British Journal of Dermatology, Vol. 190, Núm. 3, pp. 355-363

2023

  1. Consensus statement on the use of biosimilar drugs in immune-mediated diseases in Spain

    Reumatologia Clinica, Vol. 19, Núm. 8, pp. 446-454

  2. High adherence to secukinumab in patients with moderate to severe psoriasis: a long-term multicenter study in a daily practice setting

    International Journal of Dermatology

  3. Prescriptions for scabies are rapidly increasing in Spain: An ecological study with national prescription data, 2008–2021

    Journal of the European Academy of Dermatology and Venereology

2022

  1. Moderate to Severe Psoriasis in Pediatric and Young Patients: The BIOBADADERM Registry Experience

    Actas Dermo-Sifiliograficas, Vol. 113, Núm. 4, pp. 401-406

  2. The risk of hepatic adverse events of systemic medications for psoriasis: a prospective cohort study using the BIOBADADERM registry

    Journal of Dermatological Treatment, Vol. 33, Núm. 4, pp. 2110-2117

2021

  1. Food groups associated with immune-mediated inflammatory diseases: a Mendelian randomization and disease severity study

    European Journal of Clinical Nutrition, Vol. 75, Núm. 9, pp. 1368-1382

  2. Incidence of severe COVID-19 outcomes in psoriatic patients treated with systemic therapies during the pandemic: A Biobadaderm cohort analysis

    Journal of the American Academy of Dermatology, Vol. 84, Núm. 2, pp. 513-517

  3. Multidisciplinary Management of the Adverse Effects of Apremilast

    Actas Dermo-Sifiliograficas, Vol. 112, Núm. 2, pp. 134-141

  4. Sonidegib in the Treatment of Locally Advanced Basal Cell Carcinoma

    Actas Dermo-Sifiliograficas, Vol. 112, Núm. 4, pp. 295-301

2020

  1. Changing Trends in Drug Prescription and Causes of Treatment Discontinuation of First Biologic Over Ten Years in Psoriasis in the Spanish Biobadaderm Registry

    Actas Dermo-Sifiliograficas, Vol. 111, Núm. 9, pp. 752-760

  2. Long-term safety of nine systemic medications for psoriasis: A cohort study using the Spanish Registry of Adverse Events for Biological Therapy in Dermatological Diseases (BIOBADADERM) Registry

    Journal of the American Academy of Dermatology, Vol. 83, Núm. 1, pp. 139-150

  3. The risk of urinary tract infections in patients with psoriasis on systemic medications in Biobadaderm Registry: A prospective cohort study

    Journal of the American Academy of Dermatology, Vol. 82, Núm. 3, pp. 738-741

2019

  1. Genetic variation at the glycosaminoglycan metabolism pathway contributes to the risk of psoriatic arthritis but not psoriasis

    Annals of the Rheumatic Diseases, Vol. 78, Núm. 3, pp. 355-364

2018

  1. Change over time in the rates of adverse events in patients receiving systemic therapy for psoriasis: A cohort study

    Journal of the American Academy of Dermatology, Vol. 78, Núm. 4, pp. 798-800

  2. Cumulative exposure to biological therapy and risk of cancer in patients with psoriasis: a meta-analysis of Psonet studies from Israel, Italy, Spain, the U.K. and Republic of Ireland

    British Journal of Dermatology, Vol. 179, Núm. 4, pp. 863-871

  3. Description of Patients Treated with Biologic Drugs as First-Line Systemic Therapy in the BIOBADADERM Registry Between 2008 and 2016

    Actas Dermo-Sifiliograficas, Vol. 109, Núm. 7, pp. 617-623

2017

  1. Adverse events associated with discontinuation of the biologics/classic systemic treatments for moderate-to-severe plaque psoriasis: data from the Spanish Biologics Registry, Biobadaderm

    Journal of the European Academy of Dermatology and Venereology, Vol. 31, Núm. 10, pp. 1700-1708

  2. Comparison of phenotype, comorbidities, therapy and adverse events between psoriatic patients with and without psoriatic arthritis. Biobadaderm registry

    Journal of the European Academy of Dermatology and Venereology, Vol. 31, Núm. 6, pp. 1021-1028